Anastroz – Anastrozole 1mg
Anastroz is presented in the ORYVION catalog as a tablet formulation containing 1mg of anastrozole per tablet, supplied in containers of 50 tablets. Anastrozole is an orally active, nonsteroidal aromatase inhibitor that reduces estrogen production.
Its mechanism of action involves reversible inhibition of aromatase, the enzyme responsible for converting androgens into estrogens. By reducing estrogen availability, anastrozole can slow the growth of estrogen-dependent breast cancer cells. Its established medical applications include the treatment of certain breast cancers in postmenopausal women.
Product Specifications:
Commercial name: Anastroz
Listed compound: Anastrozole
Declared strength: 1mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Anastrozole can reduce bone mineral density, increasing the risk of osteoporosis and fractures, and may raise cholesterol levels. Common adverse effects include joint pain, hot flashes, weakness, and nausea. In women with pre-existing ischemic heart disease, more ischemic cardiovascular events were observed with anastrozole than with tamoxifen. Anastrozole can cause fetal harm and should not be used during pregnancy.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.